Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

A new study reveals that entacapone, a drug used to treat Parkinson’s disease, significantly disrupts the gut microbiome by ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, ...

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

Therapeutic synthetic oligonucleotides face unique analytical challenges in late-stage development. Meeting stringent regulatory requirements demands highly specific and sensitive methods like LC-MS.